The Minister of Research and Technology said that there will be 6 versions of the red and white vaccine developed by 6 institutions

Illustration of Covid-19 Vaccine. © 2020 REUTERS – Minister of Research and Technology (Menristek) / Head of the National Research and Innovation Agency (BRIN) Bambang PS Brodjonegoro said there would be six versions of the Red and White vaccine for handling Covid-19.

The six versions of the vaccine were obtained from six domestic institutions that developed the Red and White vaccine with different platforms, namely the Eijkman Institute for Molecular Biology, the Indonesian Institute of Sciences (LIPI), Gadjah Mada University, the University of Indonesia, Airlangga University and the Bandung Institute of Technology.

“Because using different platforms, six versions of the vaccine will appear automatically,” said Menristek Bambang in a virtual press conference held at the Graha BNPB Building. Jakarta, Tuesday (27/10).

The vaccine made by Eijkman with the recombinant protein sub unit platform has reached more than 50 percent progress from a laboratory scale and is planned for pre-clinical trials on animals in November 2020. LIPI is developing a vaccine with a fusion recombinant protein platform. Gadjah Mada University is developing a vaccine with a recombinant protein platform. The University of Indonesia developed a vaccine based on the DNA, mRNA, and virus-like-particles platform.

The Bandung Institute of Technology developed a vaccine with an adenovirus platform, and Airlangga University developed a vaccine with two platforms, namely adenovirus and adeno-associated virus (AAV).

Minister of Research and Technology Bambang said that the development of vaccines with various platforms is actually similar to those carried out by many foreign parties such as AstraZeneca which uses a non-replicating viral vector platform, Moderna which uses the RNA platform. Sinovac from China which uses an inactivated virus platform, and CanSino Biological Inc / Beijing Institute of Biotechnology which uses a non-replicating viral vector platform.

“But the most important thing is that the production is the same, namely the Covid-19 vaccine,” he said.

He said the different platforms used in the development of the Red and White vaccine for Covid-19 depended on the technology controlled by each institution or researcher.

“Currently six institutions are working respectively but in essence they will eventually come out with the Covid-19 vaccine and we will facilitate its production,” he said.

He said the task of research institutions or the Ministry of Research and Technology is to produce a prototype or seed for the Covid-19 vaccine, then further development will be the responsibility of PT Bio Farma to be able to carry out clinical trials and production of the vaccine. Bio Farma also plans to form a consortium with private domestic companies to be able to produce Red and White vaccines with a larger capacity. (mdk/gil)


Share on facebook
Share on pinterest
Share on twitter
Share on linkedin
Share on email


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.